Novo Nordisk will lose its patent protection on its branded semaglutide drugs Ozempic and Wegovy in Canada after not paying a maintenance fee in 2019.
Related Posts
Rep. Mark Green resigns from Congress, leaving Speaker Johnson with an even narrower Republican majority in the House
Rep. Mark Green said he was returning to the private sector to start his own business, without sharing details about the business.
Amgen says obesity drug caused up to 20% weight loss after a year, with no plateau
The results shed light on how MariTide may measure up to weight loss injections from Novo Nordisk and Eli Lilly and other experimental treatments.
Special counsel Jack Smith seeks pause in Trump classified documents case appeal
The election of Donald Trump as president prompted prosecutors to ask for pauses in three criminal cases against the Republican.